nodes	percent_of_prediction	percent_of_DWPC	metapath
Nadolol—Salbutamol—chronic obstructive pulmonary disease	0.375	1	CrCtD
Nadolol—ADRB2—chronic obstructive pulmonary disease	0.153	1	CbGaD
Nadolol—Pirbuterol—Salbutamol—chronic obstructive pulmonary disease	0.0705	0.316	CrCrCtD
Nadolol—Levobunolol—Salbutamol—chronic obstructive pulmonary disease	0.056	0.251	CrCrCtD
Nadolol—Carteolol—Salbutamol—chronic obstructive pulmonary disease	0.056	0.251	CrCrCtD
Nadolol—ADRB2—Salbutamol—chronic obstructive pulmonary disease	0.0415	0.194	CbGbCtD
Nadolol—ADRB1—Salbutamol—chronic obstructive pulmonary disease	0.0408	0.191	CbGbCtD
Nadolol—Bupranolol—Salbutamol—chronic obstructive pulmonary disease	0.0405	0.182	CrCrCtD
Nadolol—ADRB2—Formoterol—chronic obstructive pulmonary disease	0.0314	0.147	CbGbCtD
Nadolol—ADRB2—Arformoterol—chronic obstructive pulmonary disease	0.0314	0.147	CbGbCtD
Nadolol—ADRB1—Arformoterol—chronic obstructive pulmonary disease	0.0309	0.144	CbGbCtD
Nadolol—ADRB1—Formoterol—chronic obstructive pulmonary disease	0.0309	0.144	CbGbCtD
Nadolol—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.00372	0.0174	CbGbCtD
Nadolol—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.00351	0.0164	CbGbCtD
Nadolol—Extrasystoles—Aminophylline—chronic obstructive pulmonary disease	0.000423	0.0142	CcSEcCtD
Nadolol—Cardiomegaly—Prednisolone—chronic obstructive pulmonary disease	0.000402	0.0135	CcSEcCtD
Nadolol—Ventricular extrasystoles—Aminophylline—chronic obstructive pulmonary disease	0.000394	0.0132	CcSEcCtD
Nadolol—Gastritis—Roflumilast—chronic obstructive pulmonary disease	0.000343	0.0115	CcSEcCtD
Nadolol—Pirbuterol—ADRB2—chronic obstructive pulmonary disease	0.000322	0.203	CrCbGaD
Nadolol—Extrasystoles—Arformoterol—chronic obstructive pulmonary disease	0.000322	0.0108	CcSEcCtD
Nadolol—Extrasystoles—Formoterol—chronic obstructive pulmonary disease	0.000322	0.0108	CcSEcCtD
Nadolol—Extrasystoles—Salbutamol—chronic obstructive pulmonary disease	0.000304	0.0102	CcSEcCtD
Nadolol—Ventricular extrasystoles—Formoterol—chronic obstructive pulmonary disease	0.0003	0.01	CcSEcCtD
Nadolol—Ventricular extrasystoles—Arformoterol—chronic obstructive pulmonary disease	0.0003	0.01	CcSEcCtD
Nadolol—Depression—Roflumilast—chronic obstructive pulmonary disease	0.000298	0.00996	CcSEcCtD
Nadolol—Cardiomegaly—Prednisone—chronic obstructive pulmonary disease	0.000292	0.00978	CcSEcCtD
Nadolol—Disorientation—Aminophylline—chronic obstructive pulmonary disease	0.000289	0.00966	CcSEcCtD
Nadolol—Levobunolol—ADRB2—chronic obstructive pulmonary disease	0.000287	0.181	CrCbGaD
Nadolol—Atrioventricular block—Arformoterol—chronic obstructive pulmonary disease	0.00028	0.00934	CcSEcCtD
Nadolol—Atrioventricular block—Formoterol—chronic obstructive pulmonary disease	0.00028	0.00934	CcSEcCtD
Nadolol—ADRB3—Adrenoceptors—ADRB2—chronic obstructive pulmonary disease	0.000271	0.103	CbGpPWpGaD
Nadolol—Irritability—Aminophylline—chronic obstructive pulmonary disease	0.000247	0.00825	CcSEcCtD
Nadolol—Carteolol—ADRB2—chronic obstructive pulmonary disease	0.000244	0.154	CrCbGaD
Nadolol—Pancreatitis acute—Prednisone—chronic obstructive pulmonary disease	0.000231	0.00773	CcSEcCtD
Nadolol—Pulmonary oedema—Salbutamol—chronic obstructive pulmonary disease	0.000228	0.00762	CcSEcCtD
Nadolol—Sleep disorder—Arformoterol—chronic obstructive pulmonary disease	0.000227	0.0076	CcSEcCtD
Nadolol—Sleep disorder—Formoterol—chronic obstructive pulmonary disease	0.000227	0.0076	CcSEcCtD
Nadolol—Dry skin—Tiotropium—chronic obstructive pulmonary disease	0.000224	0.00747	CcSEcCtD
Nadolol—Sleep disorder—Montelukast—chronic obstructive pulmonary disease	0.000223	0.00744	CcSEcCtD
Nadolol—Cardiac failure congestive—Arformoterol—chronic obstructive pulmonary disease	0.000217	0.00725	CcSEcCtD
Nadolol—Cardiac failure congestive—Formoterol—chronic obstructive pulmonary disease	0.000217	0.00725	CcSEcCtD
Nadolol—Nasal congestion—Arformoterol—chronic obstructive pulmonary disease	0.000216	0.00722	CcSEcCtD
Nadolol—Nasal congestion—Formoterol—chronic obstructive pulmonary disease	0.000216	0.00722	CcSEcCtD
Nadolol—Disorientation—Montelukast—chronic obstructive pulmonary disease	0.000216	0.0072	CcSEcCtD
Nadolol—Bupranolol—ADRB2—chronic obstructive pulmonary disease	0.000208	0.131	CrCbGaD
Nadolol—Nasal congestion—Salbutamol—chronic obstructive pulmonary disease	0.000204	0.00682	CcSEcCtD
Nadolol—Salbutamol—ADRB2—chronic obstructive pulmonary disease	0.000195	0.123	CrCbGaD
Nadolol—Penbutolol—ADRB2—chronic obstructive pulmonary disease	0.00019	0.12	CrCbGaD
Nadolol—Hypertriglyceridaemia—Prednisone—chronic obstructive pulmonary disease	0.000186	0.00621	CcSEcCtD
Nadolol—Irritability—Montelukast—chronic obstructive pulmonary disease	0.000184	0.00615	CcSEcCtD
Nadolol—Affect lability—Salbutamol—chronic obstructive pulmonary disease	0.000183	0.00611	CcSEcCtD
Nadolol—Dry skin—Formoterol—chronic obstructive pulmonary disease	0.00018	0.00603	CcSEcCtD
Nadolol—Dry skin—Arformoterol—chronic obstructive pulmonary disease	0.00018	0.00603	CcSEcCtD
Nadolol—Irritability—Salbutamol—chronic obstructive pulmonary disease	0.000177	0.00593	CcSEcCtD
Nadolol—Mood swings—Salbutamol—chronic obstructive pulmonary disease	0.000176	0.00588	CcSEcCtD
Nadolol—Gastritis—Arformoterol—chronic obstructive pulmonary disease	0.000174	0.00582	CcSEcCtD
Nadolol—Gastritis—Formoterol—chronic obstructive pulmonary disease	0.000174	0.00582	CcSEcCtD
Nadolol—Insomnia—Roflumilast—chronic obstructive pulmonary disease	0.000172	0.00576	CcSEcCtD
Nadolol—Dyspepsia—Roflumilast—chronic obstructive pulmonary disease	0.000168	0.00561	CcSEcCtD
Nadolol—Bronchospasm—Arformoterol—chronic obstructive pulmonary disease	0.000167	0.00559	CcSEcCtD
Nadolol—Bronchospasm—Formoterol—chronic obstructive pulmonary disease	0.000167	0.00559	CcSEcCtD
Nadolol—Decreased appetite—Roflumilast—chronic obstructive pulmonary disease	0.000166	0.00554	CcSEcCtD
Nadolol—Fatigue—Roflumilast—chronic obstructive pulmonary disease	0.000164	0.00549	CcSEcCtD
Nadolol—Constipation—Roflumilast—chronic obstructive pulmonary disease	0.000163	0.00545	CcSEcCtD
Nadolol—Blood triglycerides increased—Prednisone—chronic obstructive pulmonary disease	0.000163	0.00544	CcSEcCtD
Nadolol—Visual impairment—Tiotropium—chronic obstructive pulmonary disease	0.000163	0.00543	CcSEcCtD
Nadolol—Abdominal distension—Salbutamol—chronic obstructive pulmonary disease	0.000162	0.00541	CcSEcCtD
Nadolol—ADRB1—Adrenoceptors—ADRB2—chronic obstructive pulmonary disease	0.000161	0.0613	CbGpPWpGaD
Nadolol—Alopecia—Aminophylline—chronic obstructive pulmonary disease	0.000158	0.00528	CcSEcCtD
Nadolol—Bronchospasm—Salbutamol—chronic obstructive pulmonary disease	0.000158	0.00528	CcSEcCtD
Nadolol—Conjunctivitis—Arformoterol—chronic obstructive pulmonary disease	0.000147	0.00493	CcSEcCtD
Nadolol—Conjunctivitis—Formoterol—chronic obstructive pulmonary disease	0.000147	0.00493	CcSEcCtD
Nadolol—Conjunctivitis—Montelukast—chronic obstructive pulmonary disease	0.000144	0.00483	CcSEcCtD
Nadolol—Fluid retention—Prednisolone—chronic obstructive pulmonary disease	0.000139	0.00466	CcSEcCtD
Nadolol—Conjunctivitis—Salbutamol—chronic obstructive pulmonary disease	0.000139	0.00465	CcSEcCtD
Nadolol—Vision blurred—Tiotropium—chronic obstructive pulmonary disease	0.000138	0.00463	CcSEcCtD
Nadolol—Sweating—Salbutamol—chronic obstructive pulmonary disease	0.000137	0.00459	CcSEcCtD
Nadolol—Pindolol—ADRB2—chronic obstructive pulmonary disease	0.000137	0.0865	CrCbGaD
Nadolol—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.000137	0.00457	CcSEcCtD
Nadolol—Hallucination—Montelukast—chronic obstructive pulmonary disease	0.000133	0.00444	CcSEcCtD
Nadolol—Syncope—Tiotropium—chronic obstructive pulmonary disease	0.000132	0.0044	CcSEcCtD
Nadolol—Visual impairment—Formoterol—chronic obstructive pulmonary disease	0.000131	0.00439	CcSEcCtD
Nadolol—Visual impairment—Arformoterol—chronic obstructive pulmonary disease	0.000131	0.00439	CcSEcCtD
Nadolol—Pulmonary oedema—Prednisolone—chronic obstructive pulmonary disease	0.000131	0.00437	CcSEcCtD
Nadolol—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.00013	0.00436	CcSEcCtD
Nadolol—Loss of consciousness—Tiotropium—chronic obstructive pulmonary disease	0.000129	0.00431	CcSEcCtD
Nadolol—Cough—Tiotropium—chronic obstructive pulmonary disease	0.000128	0.00428	CcSEcCtD
Nadolol—Hypertension—Tiotropium—chronic obstructive pulmonary disease	0.000127	0.00424	CcSEcCtD
Nadolol—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.000126	0.00421	CcSEcCtD
Nadolol—Shock—Aminophylline—chronic obstructive pulmonary disease	0.000125	0.00418	CcSEcCtD
Nadolol—Chest pain—Tiotropium—chronic obstructive pulmonary disease	0.000125	0.00418	CcSEcCtD
Nadolol—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.000122	0.00409	CcSEcCtD
Nadolol—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.000121	0.00405	CcSEcCtD
Nadolol—Anorexia—Aminophylline—chronic obstructive pulmonary disease	0.000121	0.00405	CcSEcCtD
Nadolol—Rash—Roflumilast—chronic obstructive pulmonary disease	0.00012	0.00402	CcSEcCtD
Nadolol—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.00012	0.00401	CcSEcCtD
Nadolol—Tinnitus—Salbutamol—chronic obstructive pulmonary disease	0.00012	0.00401	CcSEcCtD
Nadolol—Oedema—Tiotropium—chronic obstructive pulmonary disease	0.00012	0.00401	CcSEcCtD
Nadolol—Hypotension—Aminophylline—chronic obstructive pulmonary disease	0.000119	0.00397	CcSEcCtD
Nadolol—Shock—Tiotropium—chronic obstructive pulmonary disease	0.000118	0.00394	CcSEcCtD
Nadolol—Cardiac failure congestive—Prednisolone—chronic obstructive pulmonary disease	0.000118	0.00393	CcSEcCtD
Nadolol—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.000115	0.00384	CcSEcCtD
Nadolol—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000113	0.00378	CcSEcCtD
Nadolol—Visual disturbance—Prednisolone—chronic obstructive pulmonary disease	0.000112	0.00376	CcSEcCtD
Nadolol—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.000112	0.00374	CcSEcCtD
Nadolol—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.00011	0.00369	CcSEcCtD
Nadolol—Flatulence—Salbutamol—chronic obstructive pulmonary disease	0.00011	0.00369	CcSEcCtD
Nadolol—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000108	0.00362	CcSEcCtD
Nadolol—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.000108	0.0036	CcSEcCtD
Nadolol—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000106	0.00353	CcSEcCtD
Nadolol—Affect lability—Prednisolone—chronic obstructive pulmonary disease	0.000105	0.00351	CcSEcCtD
Nadolol—Cough—Formoterol—chronic obstructive pulmonary disease	0.000103	0.00346	CcSEcCtD
Nadolol—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000103	0.00346	CcSEcCtD
Nadolol—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000103	0.00343	CcSEcCtD
Nadolol—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000102	0.00342	CcSEcCtD
Nadolol—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000102	0.00342	CcSEcCtD
Nadolol—Cough—Montelukast—chronic obstructive pulmonary disease	0.000101	0.00339	CcSEcCtD
Nadolol—Fluid retention—Prednisone—chronic obstructive pulmonary disease	0.000101	0.00339	CcSEcCtD
Nadolol—Mood swings—Prednisolone—chronic obstructive pulmonary disease	0.000101	0.00338	CcSEcCtD
Nadolol—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.000101	0.00337	CcSEcCtD
Nadolol—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.000101	0.00337	CcSEcCtD
Nadolol—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.0001	0.00336	CcSEcCtD
Nadolol—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.0001	0.00335	CcSEcCtD
Nadolol—Dry mouth—Formoterol—chronic obstructive pulmonary disease	9.87e-05	0.0033	CcSEcCtD
Nadolol—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	9.87e-05	0.0033	CcSEcCtD
Nadolol—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	9.84e-05	0.00329	CcSEcCtD
Nadolol—Dry skin—Prednisolone—chronic obstructive pulmonary disease	9.77e-05	0.00327	CcSEcCtD
Nadolol—Cough—Salbutamol—chronic obstructive pulmonary disease	9.77e-05	0.00326	CcSEcCtD
Nadolol—Oedema—Formoterol—chronic obstructive pulmonary disease	9.67e-05	0.00323	CcSEcCtD
Nadolol—Oedema—Arformoterol—chronic obstructive pulmonary disease	9.67e-05	0.00323	CcSEcCtD
Nadolol—Hypertension—Salbutamol—chronic obstructive pulmonary disease	9.66e-05	0.00323	CcSEcCtD
Nadolol—ADRB3—Monoamine GPCRs—ADRB2—chronic obstructive pulmonary disease	9.59e-05	0.0365	CbGpPWpGaD
Nadolol—Chest pain—Salbutamol—chronic obstructive pulmonary disease	9.53e-05	0.00318	CcSEcCtD
Nadolol—Pulmonary oedema—Prednisone—chronic obstructive pulmonary disease	9.5e-05	0.00317	CcSEcCtD
Nadolol—Oedema—Montelukast—chronic obstructive pulmonary disease	9.48e-05	0.00317	CcSEcCtD
Nadolol—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	9.32e-05	0.00311	CcSEcCtD
Nadolol—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	9.28e-05	0.0031	CcSEcCtD
Nadolol—Oedema—Salbutamol—chronic obstructive pulmonary disease	9.13e-05	0.00305	CcSEcCtD
Nadolol—Hypotension—Formoterol—chronic obstructive pulmonary disease	9.04e-05	0.00302	CcSEcCtD
Nadolol—Hypotension—Arformoterol—chronic obstructive pulmonary disease	9.04e-05	0.00302	CcSEcCtD
Nadolol—Pruritus—Aminophylline—chronic obstructive pulmonary disease	8.99e-05	0.00301	CcSEcCtD
Nadolol—Shock—Salbutamol—chronic obstructive pulmonary disease	8.99e-05	0.003	CcSEcCtD
Nadolol—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	8.83e-05	0.00295	CcSEcCtD
Nadolol—Insomnia—Arformoterol—chronic obstructive pulmonary disease	8.75e-05	0.00292	CcSEcCtD
Nadolol—Insomnia—Formoterol—chronic obstructive pulmonary disease	8.75e-05	0.00292	CcSEcCtD
Nadolol—Anorexia—Salbutamol—chronic obstructive pulmonary disease	8.71e-05	0.00291	CcSEcCtD
Nadolol—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	8.7e-05	0.00291	CcSEcCtD
Nadolol—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	8.62e-05	0.00288	CcSEcCtD
Nadolol—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	8.62e-05	0.00288	CcSEcCtD
Nadolol—Insomnia—Montelukast—chronic obstructive pulmonary disease	8.57e-05	0.00286	CcSEcCtD
Nadolol—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	8.54e-05	0.00285	CcSEcCtD
Nadolol—Hypotension—Salbutamol—chronic obstructive pulmonary disease	8.54e-05	0.00285	CcSEcCtD
Nadolol—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	8.52e-05	0.00285	CcSEcCtD
Nadolol—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	8.52e-05	0.00285	CcSEcCtD
Nadolol—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	8.51e-05	0.00284	CcSEcCtD
Nadolol—Pruritus—Tiotropium—chronic obstructive pulmonary disease	8.48e-05	0.00283	CcSEcCtD
Nadolol—Dizziness—Aminophylline—chronic obstructive pulmonary disease	8.41e-05	0.00281	CcSEcCtD
Nadolol—Weight increased—Prednisolone—chronic obstructive pulmonary disease	8.38e-05	0.0028	CcSEcCtD
Nadolol—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	8.34e-05	0.00279	CcSEcCtD
Nadolol—Fatigue—Formoterol—chronic obstructive pulmonary disease	8.34e-05	0.00279	CcSEcCtD
Nadolol—Fatigue—Arformoterol—chronic obstructive pulmonary disease	8.34e-05	0.00279	CcSEcCtD
Nadolol—Constipation—Arformoterol—chronic obstructive pulmonary disease	8.27e-05	0.00277	CcSEcCtD
Nadolol—Constipation—Formoterol—chronic obstructive pulmonary disease	8.27e-05	0.00277	CcSEcCtD
Nadolol—Pain—Arformoterol—chronic obstructive pulmonary disease	8.27e-05	0.00277	CcSEcCtD
Nadolol—Pain—Formoterol—chronic obstructive pulmonary disease	8.27e-05	0.00277	CcSEcCtD
Nadolol—Insomnia—Salbutamol—chronic obstructive pulmonary disease	8.26e-05	0.00276	CcSEcCtD
Nadolol—Amnesia—Prednisone—chronic obstructive pulmonary disease	8.24e-05	0.00276	CcSEcCtD
Nadolol—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	8.2e-05	0.00274	CcSEcCtD
Nadolol—Fatigue—Montelukast—chronic obstructive pulmonary disease	8.17e-05	0.00273	CcSEcCtD
Nadolol—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	8.14e-05	0.00272	CcSEcCtD
Nadolol—Pain—Montelukast—chronic obstructive pulmonary disease	8.1e-05	0.00271	CcSEcCtD
Nadolol—Vomiting—Aminophylline—chronic obstructive pulmonary disease	8.08e-05	0.0027	CcSEcCtD
Nadolol—ADRB3—Amine ligand-binding receptors—ADRB2—chronic obstructive pulmonary disease	8.06e-05	0.0307	CbGpPWpGaD
Nadolol—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	8.04e-05	0.00269	CcSEcCtD
Nadolol—Rash—Aminophylline—chronic obstructive pulmonary disease	8.01e-05	0.00268	CcSEcCtD
Nadolol—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	8.01e-05	0.00268	CcSEcCtD
Nadolol—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	7.98e-05	0.00267	CcSEcCtD
Nadolol—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	7.94e-05	0.00265	CcSEcCtD
Nadolol—Cardiac failure—Prednisone—chronic obstructive pulmonary disease	7.94e-05	0.00265	CcSEcCtD
Nadolol—Dizziness—Tiotropium—chronic obstructive pulmonary disease	7.93e-05	0.00265	CcSEcCtD
Nadolol—Lethargy—Prednisone—chronic obstructive pulmonary disease	7.9e-05	0.00264	CcSEcCtD
Nadolol—Fatigue—Salbutamol—chronic obstructive pulmonary disease	7.88e-05	0.00263	CcSEcCtD
Nadolol—Constipation—Salbutamol—chronic obstructive pulmonary disease	7.81e-05	0.00261	CcSEcCtD
Nadolol—Pain—Salbutamol—chronic obstructive pulmonary disease	7.81e-05	0.00261	CcSEcCtD
Nadolol—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	7.65e-05	0.00256	CcSEcCtD
Nadolol—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	7.65e-05	0.00256	CcSEcCtD
Nadolol—Affect lability—Prednisone—chronic obstructive pulmonary disease	7.62e-05	0.00255	CcSEcCtD
Nadolol—Vomiting—Tiotropium—chronic obstructive pulmonary disease	7.62e-05	0.00255	CcSEcCtD
Nadolol—Rash—Tiotropium—chronic obstructive pulmonary disease	7.56e-05	0.00253	CcSEcCtD
Nadolol—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	7.55e-05	0.00252	CcSEcCtD
Nadolol—Nausea—Aminophylline—chronic obstructive pulmonary disease	7.55e-05	0.00252	CcSEcCtD
Nadolol—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	7.51e-05	0.00251	CcSEcCtD
Nadolol—ADRB3—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	7.5e-05	0.0285	CbGpPWpGaD
Nadolol—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	7.49e-05	0.0025	CcSEcCtD
Nadolol—Irritability—Prednisone—chronic obstructive pulmonary disease	7.39e-05	0.00247	CcSEcCtD
Nadolol—Mood swings—Prednisone—chronic obstructive pulmonary disease	7.34e-05	0.00245	CcSEcCtD
Nadolol—ADRB1—Melatonin metabolism and effects—CYP1A2—chronic obstructive pulmonary disease	7.28e-05	0.0277	CbGpPWpGaD
Nadolol—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	7.22e-05	0.00241	CcSEcCtD
Nadolol—Nausea—Tiotropium—chronic obstructive pulmonary disease	7.12e-05	0.00238	CcSEcCtD
Nadolol—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	7.11e-05	0.00238	CcSEcCtD
Nadolol—Dry skin—Prednisone—chronic obstructive pulmonary disease	7.1e-05	0.00237	CcSEcCtD
Nadolol—Asthenia—Arformoterol—chronic obstructive pulmonary disease	6.94e-05	0.00232	CcSEcCtD
Nadolol—Asthenia—Formoterol—chronic obstructive pulmonary disease	6.94e-05	0.00232	CcSEcCtD
Nadolol—Pruritus—Formoterol—chronic obstructive pulmonary disease	6.84e-05	0.00229	CcSEcCtD
Nadolol—Pruritus—Arformoterol—chronic obstructive pulmonary disease	6.84e-05	0.00229	CcSEcCtD
Nadolol—Asthenia—Montelukast—chronic obstructive pulmonary disease	6.8e-05	0.00227	CcSEcCtD
Nadolol—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	6.74e-05	0.00225	CcSEcCtD
Nadolol—Pruritus—Montelukast—chronic obstructive pulmonary disease	6.7e-05	0.00224	CcSEcCtD
Nadolol—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	6.62e-05	0.00221	CcSEcCtD
Nadolol—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	6.62e-05	0.00221	CcSEcCtD
Nadolol—ADRB3—G alpha (s) signalling events—PDE4A—chronic obstructive pulmonary disease	6.58e-05	0.025	CbGpPWpGaD
Nadolol—Asthenia—Salbutamol—chronic obstructive pulmonary disease	6.55e-05	0.00219	CcSEcCtD
Nadolol—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	6.48e-05	0.00217	CcSEcCtD
Nadolol—Pruritus—Salbutamol—chronic obstructive pulmonary disease	6.46e-05	0.00216	CcSEcCtD
Nadolol—Dizziness—Formoterol—chronic obstructive pulmonary disease	6.4e-05	0.00214	CcSEcCtD
Nadolol—Dizziness—Arformoterol—chronic obstructive pulmonary disease	6.4e-05	0.00214	CcSEcCtD
Nadolol—ADRB3—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	6.3e-05	0.024	CbGpPWpGaD
Nadolol—Dizziness—Montelukast—chronic obstructive pulmonary disease	6.27e-05	0.00209	CcSEcCtD
Nadolol—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	6.25e-05	0.00209	CcSEcCtD
Nadolol—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	6.17e-05	0.00206	CcSEcCtD
Nadolol—Vomiting—Formoterol—chronic obstructive pulmonary disease	6.15e-05	0.00206	CcSEcCtD
Nadolol—Vomiting—Arformoterol—chronic obstructive pulmonary disease	6.15e-05	0.00206	CcSEcCtD
Nadolol—Rash—Formoterol—chronic obstructive pulmonary disease	6.1e-05	0.00204	CcSEcCtD
Nadolol—Rash—Arformoterol—chronic obstructive pulmonary disease	6.1e-05	0.00204	CcSEcCtD
Nadolol—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	6.09e-05	0.00204	CcSEcCtD
Nadolol—Dermatitis—Formoterol—chronic obstructive pulmonary disease	6.09e-05	0.00204	CcSEcCtD
Nadolol—Weight increased—Prednisone—chronic obstructive pulmonary disease	6.09e-05	0.00204	CcSEcCtD
Nadolol—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	6.05e-05	0.00202	CcSEcCtD
Nadolol—Dizziness—Salbutamol—chronic obstructive pulmonary disease	6.04e-05	0.00202	CcSEcCtD
Nadolol—Vomiting—Montelukast—chronic obstructive pulmonary disease	6.02e-05	0.00201	CcSEcCtD
Nadolol—Rash—Montelukast—chronic obstructive pulmonary disease	5.97e-05	0.002	CcSEcCtD
Nadolol—Dermatitis—Montelukast—chronic obstructive pulmonary disease	5.97e-05	0.002	CcSEcCtD
Nadolol—Depression—Prednisone—chronic obstructive pulmonary disease	5.95e-05	0.00199	CcSEcCtD
Nadolol—Vomiting—Salbutamol—chronic obstructive pulmonary disease	5.81e-05	0.00194	CcSEcCtD
Nadolol—Rash—Salbutamol—chronic obstructive pulmonary disease	5.76e-05	0.00193	CcSEcCtD
Nadolol—Syncope—Prednisolone—chronic obstructive pulmonary disease	5.76e-05	0.00192	CcSEcCtD
Nadolol—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	5.75e-05	0.00192	CcSEcCtD
Nadolol—Nausea—Arformoterol—chronic obstructive pulmonary disease	5.75e-05	0.00192	CcSEcCtD
Nadolol—Nausea—Formoterol—chronic obstructive pulmonary disease	5.75e-05	0.00192	CcSEcCtD
Nadolol—ADRB1—Monoamine GPCRs—ADRB2—chronic obstructive pulmonary disease	5.69e-05	0.0217	CbGpPWpGaD
Nadolol—ADRB1—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	5.64e-05	0.0215	CbGpPWpGaD
Nadolol—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	5.64e-05	0.00189	CcSEcCtD
Nadolol—Nausea—Montelukast—chronic obstructive pulmonary disease	5.63e-05	0.00188	CcSEcCtD
Nadolol—Hypertension—Prednisolone—chronic obstructive pulmonary disease	5.54e-05	0.00185	CcSEcCtD
Nadolol—Bradycardia—Prednisone—chronic obstructive pulmonary disease	5.46e-05	0.00182	CcSEcCtD
Nadolol—Nausea—Salbutamol—chronic obstructive pulmonary disease	5.43e-05	0.00181	CcSEcCtD
Nadolol—Hallucination—Prednisone—chronic obstructive pulmonary disease	5.33e-05	0.00178	CcSEcCtD
Nadolol—ADRB1—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	5.29e-05	0.0201	CbGpPWpGaD
Nadolol—Oedema—Prednisolone—chronic obstructive pulmonary disease	5.24e-05	0.00175	CcSEcCtD
Nadolol—Shock—Prednisolone—chronic obstructive pulmonary disease	5.15e-05	0.00172	CcSEcCtD
Nadolol—ADRB1—Endothelin Pathways—EDN1—chronic obstructive pulmonary disease	5.09e-05	0.0194	CbGpPWpGaD
Nadolol—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	5.06e-05	0.00169	CcSEcCtD
Nadolol—ADRB1—Amine ligand-binding receptors—ADRB2—chronic obstructive pulmonary disease	4.79e-05	0.0182	CbGpPWpGaD
Nadolol—Insomnia—Prednisolone—chronic obstructive pulmonary disease	4.74e-05	0.00158	CcSEcCtD
Nadolol—Alopecia—Prednisone—chronic obstructive pulmonary disease	4.74e-05	0.00158	CcSEcCtD
Nadolol—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	4.7e-05	0.00157	CcSEcCtD
Nadolol—Pain—Prednisolone—chronic obstructive pulmonary disease	4.48e-05	0.0015	CcSEcCtD
Nadolol—ADRB1—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	4.45e-05	0.0169	CbGpPWpGaD
Nadolol—Vision blurred—Prednisone—chronic obstructive pulmonary disease	4.4e-05	0.00147	CcSEcCtD
Nadolol—ADRB2—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	4.35e-05	0.0166	CbGpPWpGaD
Nadolol—Syncope—Prednisone—chronic obstructive pulmonary disease	4.18e-05	0.0014	CcSEcCtD
Nadolol—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	4.1e-05	0.00137	CcSEcCtD
Nadolol—Hypertension—Prednisone—chronic obstructive pulmonary disease	4.03e-05	0.00135	CcSEcCtD
Nadolol—ADRB2—GPCRs, Other—CXCR2—chronic obstructive pulmonary disease	3.94e-05	0.015	CbGpPWpGaD
Nadolol—ADRB1—G alpha (s) signalling events—PDE4A—chronic obstructive pulmonary disease	3.91e-05	0.0149	CbGpPWpGaD
Nadolol—ADRB2—G alpha (s) signalling events—PDE4A—chronic obstructive pulmonary disease	3.82e-05	0.0145	CbGpPWpGaD
Nadolol—Oedema—Prednisone—chronic obstructive pulmonary disease	3.81e-05	0.00127	CcSEcCtD
Nadolol—Shock—Prednisone—chronic obstructive pulmonary disease	3.75e-05	0.00125	CcSEcCtD
Nadolol—ADRB1—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	3.74e-05	0.0142	CbGpPWpGaD
Nadolol—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	3.68e-05	0.00123	CcSEcCtD
Nadolol—ADRB2—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	3.66e-05	0.0139	CbGpPWpGaD
Nadolol—Anorexia—Prednisone—chronic obstructive pulmonary disease	3.63e-05	0.00121	CcSEcCtD
Nadolol—Dizziness—Prednisolone—chronic obstructive pulmonary disease	3.46e-05	0.00116	CcSEcCtD
Nadolol—Insomnia—Prednisone—chronic obstructive pulmonary disease	3.44e-05	0.00115	CcSEcCtD
Nadolol—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	3.42e-05	0.00114	CcSEcCtD
Nadolol—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	3.35e-05	0.00112	CcSEcCtD
Nadolol—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	3.33e-05	0.0127	CbGpPWpGaD
Nadolol—ADRB3—G alpha (s) signalling events—ADRB2—chronic obstructive pulmonary disease	3.33e-05	0.0127	CbGpPWpGaD
Nadolol—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	3.31e-05	0.00111	CcSEcCtD
Nadolol—Rash—Prednisolone—chronic obstructive pulmonary disease	3.3e-05	0.0011	CcSEcCtD
Nadolol—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	3.3e-05	0.0011	CcSEcCtD
Nadolol—Fatigue—Prednisone—chronic obstructive pulmonary disease	3.28e-05	0.0011	CcSEcCtD
Nadolol—Constipation—Prednisone—chronic obstructive pulmonary disease	3.26e-05	0.00109	CcSEcCtD
Nadolol—Nausea—Prednisolone—chronic obstructive pulmonary disease	3.11e-05	0.00104	CcSEcCtD
Nadolol—ADRB1—Endothelin Pathways—NOS3—chronic obstructive pulmonary disease	3.1e-05	0.0118	CbGpPWpGaD
Nadolol—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	3.01e-05	0.00101	CcSEcCtD
Nadolol—ADRB3—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	2.95e-05	0.0112	CbGpPWpGaD
Nadolol—ADRB3—Calcium Regulation in the Cardiac Cell—ADRB2—chronic obstructive pulmonary disease	2.87e-05	0.0109	CbGpPWpGaD
Nadolol—Asthenia—Prednisone—chronic obstructive pulmonary disease	2.73e-05	0.000913	CcSEcCtD
Nadolol—Pruritus—Prednisone—chronic obstructive pulmonary disease	2.69e-05	0.0009	CcSEcCtD
Nadolol—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	2.6e-05	0.000871	CcSEcCtD
Nadolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	2.53e-05	0.00962	CbGpPWpGaD
Nadolol—Dizziness—Prednisone—chronic obstructive pulmonary disease	2.52e-05	0.000841	CcSEcCtD
Nadolol—Vomiting—Prednisone—chronic obstructive pulmonary disease	2.42e-05	0.000809	CcSEcCtD
Nadolol—Rash—Prednisone—chronic obstructive pulmonary disease	2.4e-05	0.000802	CcSEcCtD
Nadolol—Dermatitis—Prednisone—chronic obstructive pulmonary disease	2.4e-05	0.000802	CcSEcCtD
Nadolol—Nausea—Prednisone—chronic obstructive pulmonary disease	2.26e-05	0.000756	CcSEcCtD
Nadolol—ABCB1—Allograft Rejection—IL13—chronic obstructive pulmonary disease	2.08e-05	0.00791	CbGpPWpGaD
Nadolol—ADRB1—G alpha (s) signalling events—ADRB2—chronic obstructive pulmonary disease	1.97e-05	0.00752	CbGpPWpGaD
Nadolol—ADRB2—GPCRs, Other—HTR2A—chronic obstructive pulmonary disease	1.93e-05	0.00736	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	1.93e-05	0.00733	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—IL17A—chronic obstructive pulmonary disease	1.91e-05	0.00728	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—RAPGEF3—chronic obstructive pulmonary disease	1.9e-05	0.00722	CbGpPWpGaD
Nadolol—ADRB2—Arf6 signaling events—EGFR—chronic obstructive pulmonary disease	1.88e-05	0.00714	CbGpPWpGaD
Nadolol—ADRB3—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	1.85e-05	0.00705	CbGpPWpGaD
Nadolol—ADRB1—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	1.75e-05	0.00667	CbGpPWpGaD
Nadolol—ADRB2—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	1.71e-05	0.00652	CbGpPWpGaD
Nadolol—ADRB1—Calcium Regulation in the Cardiac Cell—ADRB2—chronic obstructive pulmonary disease	1.7e-05	0.00649	CbGpPWpGaD
Nadolol—ABCB1—HIF-1-alpha transcription factor network—HMOX1—chronic obstructive pulmonary disease	1.61e-05	0.00613	CbGpPWpGaD
Nadolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	1.59e-05	0.00604	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	1.58e-05	0.006	CbGpPWpGaD
Nadolol—ABCB1—HIF-1-alpha transcription factor network—EDN1—chronic obstructive pulmonary disease	1.52e-05	0.00578	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	1.5e-05	0.00571	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	1.47e-05	0.00559	CbGpPWpGaD
Nadolol—ADRB3—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	1.45e-05	0.00551	CbGpPWpGaD
Nadolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	1.42e-05	0.00539	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	1.39e-05	0.00531	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	1.35e-05	0.00514	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—IL10—chronic obstructive pulmonary disease	1.3e-05	0.00495	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	1.24e-05	0.00473	CbGpPWpGaD
Nadolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	1.24e-05	0.00472	CbGpPWpGaD
Nadolol—ABCB1—HIF-1-alpha transcription factor network—LEP—chronic obstructive pulmonary disease	1.24e-05	0.0047	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	1.23e-05	0.00467	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	1.21e-05	0.0046	CbGpPWpGaD
Nadolol—ABCB1—HIF-1-alpha transcription factor network—NOS2—chronic obstructive pulmonary disease	1.15e-05	0.00438	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	1.14e-05	0.00435	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	1.12e-05	0.00425	CbGpPWpGaD
Nadolol—ADRB1—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	1.1e-05	0.00418	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	1.09e-05	0.00414	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	1.08e-05	0.00411	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	9.88e-06	0.00376	CbGpPWpGaD
Nadolol—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—chronic obstructive pulmonary disease	9.7e-06	0.00369	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	9.56e-06	0.00364	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	9.44e-06	0.00359	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	9.41e-06	0.00358	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	9.36e-06	0.00356	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	9.16e-06	0.00349	CbGpPWpGaD
Nadolol—ADRB1—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	8.59e-06	0.00327	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	8.41e-06	0.0032	CbGpPWpGaD
Nadolol—ADRB2—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	8.4e-06	0.0032	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	8.23e-06	0.00313	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	8.01e-06	0.00305	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	7.84e-06	0.00298	CbGpPWpGaD
Nadolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	7.66e-06	0.00292	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	7.36e-06	0.0028	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	7.28e-06	0.00277	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	7.24e-06	0.00276	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	7.2e-06	0.00274	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	7.17e-06	0.00273	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	7.12e-06	0.00271	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—CXCL8—chronic obstructive pulmonary disease	7.11e-06	0.00271	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	6.83e-06	0.0026	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—IL1B—chronic obstructive pulmonary disease	6.82e-06	0.0026	CbGpPWpGaD
Nadolol—ABCB1—HIF-1-alpha transcription factor network—VEGFA—chronic obstructive pulmonary disease	6.67e-06	0.00254	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	6.46e-06	0.00246	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	6.41e-06	0.00244	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	6.32e-06	0.0024	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	6.27e-06	0.00239	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	6.2e-06	0.00236	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	6.1e-06	0.00232	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	5.86e-06	0.00223	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	5.84e-06	0.00222	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	5.83e-06	0.00222	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—VEGFA—chronic obstructive pulmonary disease	5.78e-06	0.0022	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	5.74e-06	0.00218	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	5.67e-06	0.00216	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	5.6e-06	0.00213	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	5.55e-06	0.00211	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	5.54e-06	0.00211	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	5.48e-06	0.00209	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	5.34e-06	0.00203	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—APIP—chronic obstructive pulmonary disease	5.32e-06	0.00203	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	5.3e-06	0.00202	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	4.95e-06	0.00188	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	4.85e-06	0.00184	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	4.55e-06	0.00173	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	4.45e-06	0.00169	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	4.3e-06	0.00164	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	4.27e-06	0.00162	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	4.2e-06	0.0016	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	4.05e-06	0.00154	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—KL—chronic obstructive pulmonary disease	3.97e-06	0.00151	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	3.68e-06	0.0014	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	3.66e-06	0.00139	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	3.62e-06	0.00138	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	3.54e-06	0.00135	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.53e-06	0.00134	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	3.46e-06	0.00132	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	3.46e-06	0.00132	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	3.43e-06	0.00131	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	3.39e-06	0.00129	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	3.39e-06	0.00129	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	3.3e-06	0.00125	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	3.29e-06	0.00125	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	3.27e-06	0.00125	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	3.22e-06	0.00122	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.19e-06	0.00121	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	3.17e-06	0.00121	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	3.1e-06	0.00118	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	2.99e-06	0.00114	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	2.97e-06	0.00113	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.88e-06	0.00109	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	2.86e-06	0.00109	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	2.85e-06	0.00108	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.81e-06	0.00107	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	2.73e-06	0.00104	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—LEP—chronic obstructive pulmonary disease	2.66e-06	0.00101	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	2.62e-06	0.000996	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	2.56e-06	0.000976	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.53e-06	0.000964	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.48e-06	0.000943	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	2.44e-06	0.00093	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.36e-06	0.000896	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.3e-06	0.000877	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	2.19e-06	0.000833	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	2.17e-06	0.000827	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	2.15e-06	0.00082	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.09e-06	0.000795	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.99e-06	0.000759	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.96e-06	0.000745	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.94e-06	0.000739	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.91e-06	0.000729	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.9e-06	0.000723	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.87e-06	0.000713	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	1.85e-06	0.000705	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.78e-06	0.000676	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.77e-06	0.000673	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.77e-06	0.000672	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.74e-06	0.000662	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.73e-06	0.000657	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.7e-06	0.000647	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	1.69e-06	0.000643	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	1.68e-06	0.00064	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.66e-06	0.000633	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.64e-06	0.000625	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.6e-06	0.000609	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.58e-06	0.000601	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.56e-06	0.000593	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.55e-06	0.000588	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.44e-06	0.000547	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.32e-06	0.000502	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.3e-06	0.000494	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.3e-06	0.000494	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.29e-06	0.000492	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.28e-06	0.000488	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.27e-06	0.000484	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.24e-06	0.000472	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.21e-06	0.000461	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.19e-06	0.000454	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.18e-06	0.00045	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.16e-06	0.000441	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.13e-06	0.000431	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.09e-06	0.000413	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.05e-06	0.0004	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.03e-06	0.000391	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	9.98e-07	0.00038	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IL6—chronic obstructive pulmonary disease	9.93e-07	0.000378	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	9.76e-07	0.000372	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	9.49e-07	0.000361	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	9.29e-07	0.000353	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	8.53e-07	0.000324	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	8.34e-07	0.000317	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	7.83e-07	0.000298	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	7.69e-07	0.000293	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	7.67e-07	0.000292	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	7.65e-07	0.000291	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	7.51e-07	0.000286	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	7.36e-07	0.00028	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	6.44e-07	0.000245	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	6.3e-07	0.00024	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.9e-07	0.000224	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.77e-07	0.00022	CbGpPWpGaD
